Answers are grounded in this paper and cite their sources.
Four-pillar therapy—renin–angiotensin system inhibitors, sodium–glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide 1 receptor agonists—is increasingly applied to improve kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease (CKD). However, landmark trials underpinning current recommendations largely enrolled participants down to estimated glomerular filtration rate thresholds of approximately 20–30 mL/min/1.73 m 2 , leaving uncertainty in CKD G4–G5. This uncertainty contributes to an implementation gap in advanced CKD: missing pillars are often not initiated, therapies are interrupted during clinical complications, and they are not re-initiated once acute triggers resolve despite high absolute kidney and cardiovascular risk. This narrative review summarizes what current evidence does—and does not—support for initiating, continuing, temporarily withholding, discontinuing, and re-initiating each pillar in type 2 diabetes and CKD G4–G5. We integrate post-hoc and subgroup analyses of landmark trials, meta-analyses and pooled analyses including low-eGFR strata, and observational real-world data. The main practical message is that current evidence generally supports a monitoring-based approach to four-pillar therapy in CKD G4, whereas decisions in CKD G5 remain more individualized and explicitly extrapolative. For clinicians, the key priority is to identify missing pillars, avoid unnecessary permanent discontinuation, and use structured re-initiation when clinically appropriate.
No takes yet. Share an insight, caveat, or question.
Yamanouchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: